ISEE
-0.75 (3.13%)
23.24
04:00 PM
V: 1.65M
C: 23.24
L: 23.16
H: 24.10
O: 23.58
loading chart ...
  • 1d
  • 5d
  • 1m
  • 3m
  • 6m
  • ytd
  • 1y
  • 2y
  • 5y
  • max

General
Line Type
Scale Type
Ordinate Axis
Background
Area Color
Area Gradient
Up / Down Area
Show Volume
Volume SMA
Comparison
  • State Street Updates Holdings in IVERIC bio (ISEE)
    •

  • The Manufacturers Life Insurance Company Has $2.55 Million ...
    •

  • 2023-02-02 | NDAQ:ISEE | Press Release | IVERIC bio Inc.
    •

  • NCSA supercomputers aid in fighting climate change
    •

  • Opportunities Abound: Small Cap Outlook 2023
    •

  • Why Is Iveric Bio (ISEE) Stock Up 25% Today?
    •

  • IVERIC bio, Inc. (ISEE) Q3 2022 Earnings Call Transcript
    •

  • Iveric Bio to Present at Upcoming Investor Conferences
    •

  • Apellis Pharma Crashes On Unexpected Delay For Eye Drug — A Boon For Iveric Bio
    •

  • These Were The Five Best And Worst Performing Mid-Cap Stocks In September 2022
    •

  • Iveric Bio to Present Top-line Results for Avacincaptad Pegol from Phase 3 GATHER2 Clinical Trial in Geographic Atrophy at AAO 2022 Annual Meeting
    •

  • IVERIC bio (ISEE) Posts Positive Top-Line Data From GA Study
    •

  • Iveric bio: Further Upside Possible Based On Expanded Opportunities With Zimura
    •

  • Why Is Iveric Bio (ISEE) Stock Up 56% Today?
    •

  • 7 Cheap Biotech Stocks to Buy Now
    •

  • IVERIC bio, Inc. (ISEE) CEO Glenn Sblendorio on Q2 2022 Results - Earnings Call Transcript
    •

  • Iveric Bio to Report Second Quarter 2022 Financial Results and Host Conference Call on Tuesday, July 26, 2022
    •

  • Trial Results Set to Make or Break Small-Cap Pharma Stocks
    •

  • IVERIC bio: A First Take
    •

  • Biopharmaceutical Stocks: The Bottoming Process Is Playing Out
    •

  • Iveric Bio to Present at the UBS Global Healthcare Conference 2022
    •

  • IVERIC bio, Inc. (ISEE) CEO Glenn Sblendorio on Q1 2022 Results - Earnings Call Transcript
    •

  • Wednesdays With Wedbush: 3 Smid-Cap Biotech Stock Picks
    •

  • Learning Lessons From 3 Stocks Flourishing In A Desperate Biotech Bear Market
    •

  • IVERIC bio, Inc. (ISEE) CEO Glenn Sblendorio on Q4 2021 Results - Earnings Call Transcript
    •

  • IVERIC bio (ISEE) is on the Move, Here's Why the Trend Could be Sustainable
    •

  • 7 A-Rated Biotechs to Buy for the Long Run
    •

  • IVERIC bio, Inc. (ISEE) CEO Glenn Sblendorio on Q3 2021 Results - Earnings Call Transcript
    •

  • Apellis' Loss Is Iveric Bio's Gain In Lucrative Eye Disease Field
    •

  • ISEE Stock: Why It Significantly Increased Yesterday
    •

  • Iveric Bio to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
    •

  • Here's Why Iveric Bio Stock Is Rocketing Higher Today
    •

  • ISEE Stock: Why Rival Eye Drug Developer's Disappointment Is a Boon to IVERIC bio
    •

  • Why IVERIC Bio Shares Are Soaring Today
    •

  • Why Are Iveric Bio Shares Surging In Premarket Friday?
    •

  • New Strong Sell Stocks for August 18th
    •

  • Implied Volatility Surging for IVERIC bio (ISEE) Stock Options
    •

  • IVERIC bio, Inc. (ISEE) CEO Glenn Sblendorio on Q2 2021 Results - Earnings Call Transcript
    •

  • Iveric Bio Reports Second Quarter 2021 Operational Highlights and Financial Results
    •

  • Iveric Bio Completes Patient Enrollment of GATHER2 Pivotal Clinical Trial of Zimura® Ahead of Schedule
    •

  • Small-Cap Stocks To Watch After CYTK Sheds Spotlight On Biotech
    •

  • Iveric Bio Appoints Christopher Simms as Chief Commercial Officer
    •

  • IVERIC bio (ISEE) Enters Overbought Territory
    •

  • Iveric Bio Raises $100M Via Equity To Fund Zimura Development In Geographic Atrophy
    •

  • IVERIC bio, Inc. Announces Pricing of $100 Million Public Offering of Common Stock
    •

  • IVERIC bio, Inc. Announces Proposed Offering of Common Stock
    •

  • Do Options Traders Know Something About IVERIC bio (ISEE) Stock We Don't?
    •

  • IVERIC bio Stock Increased 11.87%: Why It Happened
    •

  • ISEE Stock Price Increases Over 30% Pre-Market: Why It Happened
    •

  • Iveric Bio Receives FDA Agreement Under Special Protocol Assessment (SPA) for GATHER2 Phase 3 Clinical Trial of Zimura® in Geographic Atrophy Secondary to Age-Related Macular Degeneration
    •

  • Iveric Bio Reveals Positive Post-Hoc Analyses Of Zimura In Dry Age-Related Macular Degeneration
    •

  • Iveric Bio to Present Zimura® GATHER2 Enrollment and Retention Updates and New GATHER1 Post-Hoc Analyses Today at its Dry Age-Related Macular Degeneration Virtual Symposium for Investors
    •

  • Iveric Bio to Host Investor Symposium on Dry Age-Related Macular Degeneration on June 18, 2021
    •

  • IVERIC bio, Inc. (ISEE) CEO Glenn Sblendorio on Q1 2021 Results - Earnings Call Transcript
    •

  • New Strong Sell Stocks for April 26th
    •

  • New Strong Sell Stocks for April 21st
    •

  • New Strong Sell Stocks for April 6th
    •

  • David R. Guyer, MD to Step Down from Iveric Bio Board to Rejoin Venture Fund
    •

  • Iveric Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    •

  • IVERIC bio, Inc. (ISEE) CEO Glenn Sblendorio on Q4 2020 Results - Earnings Call Transcript
    •

  • Iveric Bio Reports Fourth Quarter and Year End 2020 Operational Highlights and Financial Results
    •

  • Iveric Bio to Present at the Cowen 41st Annual Health Care Conference
    •

  • IVERIC bio, Inc. (ISEE) CEO Glenn Sblendorio on Q3 2020 Results - Earnings Call Transcript
    •

  • 4 Health Stocks Stonepine Capital Loves (1 Has Gained 233% Since September 29)
    •

  • Europe Dry Age-Related Macular Degeneration Market and Competitive Landscape Report 2020 - ResearchAndMarkets.com
    •

  • Europe Wet Age-Related Macular Degeneration Market and Competitive Landscape Report 2020: Pipeline, Epidemiology, Market Valuations, Drug Sales, Market Forecast, Drug Forecasts, & Market Shares - ResearchAndMarkets.com
    •

  • IVERIC bio Reports Second Quarter 2020 Operational Highlights and Financial Results
    •

  • IVERIC bio to Present at the 2020 Wedbush PacGrow Healthcare Virtual Conference
    •

  • World Retinal Biologics Market: Growth, Trends and Forecasts (2020-2025) - ResearchAndMarkets.com
    •

  • IVERIC bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
    •

  • Worsening eye sight doesn't stop for Covid, neither did we
    •

  • IVERIC bio to Report Second Quarter 2020 Financial Results and Host Conference Call on Wednesday, August 5, 2020
    •

  • What You Need To Know About IVERIC bio, Inc.'s (NASDAQ:ISEE) Investor Composition
    •

  • Did Hedge Funds Make The Right Call On IVERIC bio, Inc. (ISEE) ?
    •

  • IVERIC bio Announces the Addition of Mark S. Blumenkranz, M.D., M.M.S., to its Board of Directors
    •

  • Two Sigma Advisers LP Has $258,000 Stock Position in IVERIC bio Inc (NASDAQ:ISEE)
    •

  • 17,273 Shares in IVERIC bio Inc (NASDAQ:ISEE) Purchased by JPMorgan Chase & Co.
    •

  • Moving Average Crossover Alert: IVERIC bio
    •

  • Iveric's Trial Progress And Other News: The Good, Bad And Ugly Of Biopharma
    •

  • Juvenile Macular Degeneration (JMD) Industry Report 2020: Overview of Therapeutic Pipeline Activity and Assessment of Products - ResearchAndMarkets.com
    •

  • IVERIC bio Announces First Patient Dosed in Second Zimura® Phase 3 Clinical Trial for the Treatment of Geographic Atrophy Secondary to Age-Related Macular Degeneration
    •

  • Iveric Bio: Pick Up Post-Fundraising Low And Hold For Good News
    •

  • Two Sigma Investments LP Invests $675,000 in IVERIC bio Inc (NASDAQ:ISEE)
    •

  • Regeneron Pharmaceuticals : to Vigorously Defend Allegations Related to Contributions to a Patient Assistance Charity in 2013 and Early 2014 | MarketScreener
    •

  • 822,050 Shares in IVERIC bio Inc (NASDAQ:ISEE) Acquired by Deutsche Bank AG
    •

  • IVERIC bio, Inc. Announces Closing of Public Offering and Concurrent Private Placement with $160 Million in Gross Proceeds
    •

  • NOVARTIS AG : Buy rating from Oddo | MarketScreener
    •

  • Bayer : contributes an additional 50 million units of treatment to the World Federation of Hemophilia Humanitarian Aid Program | MarketScreener
    •

  • Novartis : discontinues hydroxychloroquine clinical trial based on slow enrollment, remains committed to pandemic research efforts | MarketScreener
    •

  • IVERIC bio Inc (NASDAQ:ISEE) Receives Consensus Rating of “Hold” from Analysts
    •

  • IVERIC bio, Inc. Announces Pricing of Upsized Public Offering of Common Stock and Pre-Funded Warrants
    •

  • IVERIC bio, Inc. Announces Proposed Offering of Common Stock and Pre-Funded Warrants and Concurrent Private Placement
    •

  • Specsavers stores have reopened for eye tests across Cambridgeshire
    •

  • Specsavers: England stores open for routine eye tests from today - what to expect
    •

  • Cowen & Co. Maintains a Buy Rating on IVERIC bio (ISEE) - Markets
    •

  • Novartis : Cosentyx receives FDA approval for new indication to treat active non-radiographic axial spondyloarthritis | MarketScreener
    •

  • Is IVERIC bio, Inc. (ISEE) Going to Burn These Hedge Funds?
    •

  • Novartis : manufactures and donates 27,000 units of hand sanitizer to New York State | MarketScreener
    •

  • IVERIC bio Announces Positive Zimura 18 Month Data Supporting the 12 Month Efficacy Findings: Continuous Positive Treatment Effect with Favorable Safety Profile in Geographic Atrophy Secondary to Age-Related Macular Degeneration in a Phase 3 Trial
    •

  • IVERIC bio to Announce Zimura® 18 Month Data from the OPH2003 Phase 3 Clinical Trial in Geographic Atrophy Secondary to Age-Related Macular Degeneration and Host Conference Call on Monday, June 15, 2020
    •

News ...
State Street Updates Holdings in IVERIC bio (ISEE) news.google.com •
The Manufacturers Life Insurance Company Has $2.55 Million ... news.google.com •
2023-02-02 | NDAQ:ISEE | Press Release | IVERIC bio Inc. news.google.com •
NCSA supercomputers aid in fighting climate change news.google.com •
Opportunities Abound: Small Cap Outlook 2023 news.google.com •
Why Is Iveric Bio (ISEE) Stock Up 25% Today? investorplace.com •
Profile ...
IVERIC bio, Inc., a biopharmaceutical company, discovers and develops novel treatments for retinal diseases with a focus on age-related and orphan inherited retinal diseases (IRDs). The company develops Zimura, an inhibitor of complement factor C5 comprising GATHER1, which has completed Phase 2/3 clinical trial; and GATHER2 that is in Phase 3 clinical trial for the treatment of geographic atrophy (GA) secondary to dry age-related macular degeneration (AMD). It also develops STAR or OPH2005 that is in Phase 2b clinical trial for the treatment of leber congenital amaurosis type 10 (LCA10) and autosomal recessive stargardt disease (STGD1); IC-500, a high temperature requirement A serine peptidase 1 protein inhibitors for the treatment of GA and other age-related retinal diseases; IC-100 for the treatment of rhodopsin-mediated autosomal dominant retinitis pigmentosa; and IC-200 for the treatment of IRDs associated with mutations in the BEST1 gene. In addition, the company develops OPH2001 that has completed Phase 1/2a clinical trial of various doses of Zimura monotherapy for the treatment of GA; OPH2000, which has completed Phase 1/2a clinical trial of various doses of Zimura administered in combination with Lucentis for the treatment of wet AMD; OPH2007 that has completed Phase 2a clinical trial for the treatment of wet AMD; and OPH2002, which has completed Phase 2a clinical trial for the treatment of idiopathic polypoidal choroidal vasculopathy. Its discovery and research programs include miniCEP290 program for LCA10; miniABCA4 Program for STGD1; and miniUSH2A Program for usher syndrome type 2A-Related IRDs. The company was formerly known as Ophthotech Corporation and changed its name to IVERIC bio, Inc. in April 2019. The company was incorporated in 2007 and is based in Parsippany, New Jersey.
Earning ...
Date For Estimate Reported Surprise surprise %
2023-02-23 2022-12 -0.37 N/A N/A N/A
2022-11-03 2022-09 -0.4 -0.35 0.05 12.50%
2022-07-26 2022-06 -0.31 -0.41 -0.1 -32.26%
2022-05-04 2022-03 -0.29 -0.29 N/A N/A
2022-02-24 2021-12 -0.24 -0.29 -0.05 -20.83%
2021-11-09 2021-09 -0.29 -0.23 0.06 20.69%
Upgrade / Downgrade ...
Date Firm Action From To
2022-11-10 Jefferies Downgrade Buy Hold
2022-11-04 HC Wainwright & Co. Upgrade Buy
2022-09-08 Stifel Upgrade Buy
2022-09-07 Guggenheim Upgrade Buy
2022-09-07 Baird Upgrade Outperform
2022-09-06 B. Riley Securities Downgrade Neutral Sell
Insider Holder ...
Date Name Relation Quantity Description
2022-07-14 BLUMENKRANZ MARK S Director 17.50K Conversion of Exercise of derivative security
2023-01-02 CARROLL DAVID FRANCIS Chief Financial Officer 68.47K Sale
2023-01-01 DUGEL PRAVIN U President 148.72K Conversion of Exercise of derivative security
2022-12-12 GIBNEY ANTHONY S. Officer 42.79K Conversion of Exercise of derivative security
2022-05-10 GRAVES ADRIENNE L Director 7.50K Conversion of Exercise of derivative security
2022-05-10 HENDERSON JANE Director 7.50K Conversion of Exercise of derivative security
Institution Ownership ...
Report Date Organization Position Value Percentage
2022-09-29 Blackrock Inc. 8.13M 188.83M 6.73%
2022-09-29 Deep Track Capital, LP 7.00M 162.68M 5.80%
2022-09-29 State Street Corporation 6.24M 145.12M 5.17%
2022-09-29 Vanguard Group, Inc. (The) 6.12M 142.15M 5.07%
2022-09-29 Avoro Capital Advisors LLC 5.90M 137.12M 4.89%
2022-09-29 Janus Henderson Group PLC 5.11M 118.84M 4.24%
Fund Ownership ...
Report Date Organization Position Value Percentage
2022-12-30 SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF 3.81M 88.61M 3.16%
2022-09-29 Vanguard Total Stock Market Index Fund 3.48M 80.86M 2.88%
2022-12-30 iShares Russell 2000 ETF 3.06M 71.08M 2.53%
2022-09-29 Smallcap World Fund 2.16M 50.29M 1.79%
2022-09-29 Price (T.Rowe) Health Sciences Fund 1.61M 37.32M 1.33%
2022-09-29 Vanguard Extended Market Index Fund 1.50M 34.83M 1.24%
Loading More Posts
  • Oldest to Newest
  • Newest to Oldest
  • Most Votes
Reply
  • Reply as topic
Log in to reply
This topic has been deleted. Only users with topic management privileges can see it.
  • C
    csrqf84t9y last edited by

    Take profits and head too $OCGN for there eye and Vaxx run next…

    1 Reply Last reply Reply Quote 0
    • E
      evelliquette last edited by

      $ISEE me shorting this one……it’s going down

      1 Reply Last reply Reply Quote 0
      • H
        hu7rb5jzei last edited by

        Only the big dogs know. Us retail slobs have to guess on the up one no news.

        1 Reply Last reply Reply Quote 0
        • H
          hu7rb5jzei last edited by

          Good luck on the cash secured puts. I hope you don’t get burned. Almost too good to be true.

          1 Reply Last reply Reply Quote 0
          • H
            hu7rb5jzei last edited by

            Something is Brewing.

            1 Reply Last reply Reply Quote 0
            • H
              hu7rb5jzei last edited by

              Will it touch 11 or 9 first?

              1 Reply Last reply Reply Quote 0
              • H
                hu7rb5jzei last edited by

                Why is this selling off so hard?

                1 Reply Last reply Reply Quote 0
                • D
                  dcschaap last edited by

                  $ISEE you at $10!

                  1 Reply Last reply Reply Quote 0
                  • M
                    maynall44 last edited by

                    $OBSV: Surprise earning by 113% above est $16-$37
                    .
                    $CAPR : Covid-19 Play...News coming this month 14th

                    $MARK : Still time to get in under $4 very under value.

                    1 Reply Last reply Reply Quote 0
                    • 1 / 1
                    • First post
                      Last post